BioCentury
ARTICLE | Clinical News

Roclatan netarsudil/latanoprost: Phase III data

September 19, 2016 7:00 AM UTC

Top-line data from the double-blind, U.S. Phase III Mercury 1 trial in 718 patients with open-angle glaucoma or ocular hypertension with a baseline IOP of >20 to <36 mmHg showed that once-daily Roclat...